Great excitement reigned at the Worcester SATVI Field Site when the first baby participant in the IMPAACT P 1113 Study was vaccinated with the Aeras-404 candidate TB vaccine.
According to Principal Investigator Dr Michele Tameris, “IMPAACT P1113/Aeras C-015-404, a collaborative study, is a multicentre trial of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) and is sponsored by Aeras in conjunction with the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).”
Participating babies will be between 9 and 14 weeks old and will receive 3 doses of AERAS- 404 with follow up for about 15 months. Three other sites are part of this trial - KIDCRU at Stellenbosch University, PHRU in Johannesburg and Shandukani in Soweto.
Source: SATVI